We have worked with many clients to develop drugs to a range of cancers and are glad to see the Movember foundation raise awareness of these diseases.
Belfast, United Kingdom (PRWEB UK) 31 October 2013
Fusion Antibodies Ltd has today announced a donation to support the worldwide Movember phenomenon. Starting in 2003 with just 30 people in Melbourne Australia, the Movember project now boasts over 1.1 million participants in 21 countries with funds raised in excess of $141 million last year alone. The project not only supports men’s mental health but two deadly forms of cancer which Fusion Antibodies have had the fortune of developing drugs for in the past.
Fusion Antibodies is a UK-based life science company which focuses on development of humanized antibody therapies to a range of diseases including cancer. "We are proud to support Dr Buick and the Movember foundation to change the face of men's health. We have worked with many clients to develop drugs to a range of cancers and are glad to see the Movember foundation raise awareness of these diseases," says Andrew Glover, Business Development at Fusion Antibodies.
Fusion Antibodies' donation to the fund will hopefully be the first of many donations to Richard's Mobro page as they encourage clients and contacts of the company to pledge to the cause.
About Fusion Antibodies
Fusion Antibodies, a UK-based life science company, with innovative technologies and world-class expert services for antibody drug discovery, are specialists in production of High Quality Humanized Monoclonal Antibodies and Antibody Engineering Projects. With 12+ years of experience in the medical research industry, including two Antibodies in clinical and pre-clinical trials, Fusion Antibodies have extensive experience in accelerating therapeutic drug research towards the clinic.
Fusion Antibodies has the knowledge and expertise to build and deliver a bespoke package of the services you need to achieve outstanding results. They provide Royalty Free Antibody Humanization of Monoclonal Antibodies and using their next generation in silico CDRx™ technology, they have modernized the traditional CDR grafting technique. Fully humanized monoclonal antibodies are an essential step in the progression of therapeutic drugs to the clinic and the in-house expertise at Fusion Antibodies ensures its success.
Visit their website at http://www.fusionantibodies.com to find out more.